

# Mohammad M Sajadi

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1340220/publications.pdf>

Version: 2024-02-01

73  
papers

3,286  
citations

185998

28  
h-index

168136

53  
g-index

79  
all docs

79  
docs citations

79  
times ranked

6335  
citing authors

#	ARTICLE	IF	CITATIONS
1	Use of oral polio vaccine and the incidence of COVID-19 in the world. PLoS ONE, 2022, 17, e0265562.	1.1	17
2	CoughNet-V2: A Scalable Multimodal DNN Framework for Point-of-Care Edge Devices to Detect Symptomatic COVID-19 Cough. , 2022, , .		5
3	Determining the SARS-CoV-2 serological immunoassay test performance indices based on the test results frequency distribution. Biochemia Medica, 2022, 32, 217-223.	1.2	1
4	Binding and Neutralization Antibody Titers After a Single Vaccine Dose in Health Care Workers Previously Infected With SARS-CoV-2. JAMA - Journal of the American Medical Association, 2021, 325, 1467.	3.8	311
5	Rational Engraftment of Quaternary-Interactive Acidic Loops for Anti-HIV-1 Antibody Improvement. Journal of Virology, 2021, 95, .	1.5	3
6	SARS-CoV-2 vaccines for all but a single dose for COVID-19 survivors. EBioMedicine, 2021, 68, 103401.	2.7	58
7	Safety and immunogenicity of an HIV-1 gp120-CD4 chimeric subunit vaccine in a phase 1a randomized controlled trial. Vaccine, 2021, 39, 3879-3891.	1.7	3
8	Near-Pan-neutralizing, Plasma Deconvoluted Antibody N49P6 Mimics Host Receptor CD4 in Its Quaternary Interactions with the HIV-1 Envelope Trimer. MBio, 2021, 12, e0127421.	1.8	4
9	Role of miR-2392 in driving SARS-CoV-2 infection. Cell Reports, 2021, 37, 109839.	2.9	52
10	Defining variant-resistant epitopes targeted by SARS-CoV-2 antibodies: A global consortium study. Science, 2021, 374, 472-478.	6.0	228
11	Combined cART including Tenofovir Disoproxil, Emtricitabine, and Dolutegravir has potent therapeutic effects in HIV-1 infected humanized mice. Journal of Translational Medicine, 2021, 19, 453.	1.8	2
12	Single-Dose Ad26.COVS Vaccine Room for Improvement. JAMA Network Open, 2021, 4, e2133012.	2.8	3
13	COVID-19 Infection Among Women in Iran Exposed vs Unexposed to Children Who Received Attenuated Poliovirus Used in Oral Polio Vaccine. JAMA Network Open, 2021, 4, e2135044.	2.8	18
14	Successful transfer of anti-SARS-CoV-2 immunity using convalescent plasma in an MM patient with hypogammaglobulinemia and COVID-19. Blood Advances, 2020, 4, 4864-4868.	2.5	20
15	Variability of CD4+ Cell Counts in HIV-Uninfected Volunteers Who Are Eligible for a Phase I HIV Vaccine Study. Journal of Acquired Immune Deficiency Syndromes (1999), 2020, 84, 37-44.	0.9	1
16	Temperature, Humidity, and Latitude Analysis to Estimate Potential Spread and Seasonality of Coronavirus Disease 2019 (COVID-19). JAMA Network Open, 2020, 3, e2011834.	2.8	496
17	Rate of re-positive RT-PCR test among patients recovered from COVID-19. Biochemia Medica, 2020, 30, 355-356.	1.2	27
18	Performance of nucleocapsid and spike-based SARS-CoV-2 serologic assays. PLoS ONE, 2020, 15, e0237828.	1.1	67

#	ARTICLE	IF	CITATIONS
19	Temperature and Latitude Analysis to Predict Potential Spread and Seasonality for COVID-19. SSRN Electronic Journal, 2020, , 3550308.	0.4	288
20	Provir/Latitude 45 study: A step towards a multi-epitopic CTL vaccine designed on archived HIV-1 DNA and according to dominant HLA I alleles. PLoS ONE, 2019, 14, e0212347.	1.1	4
21	Broadly Neutralizing Antibodies against HIV: Back to Blood. Trends in Molecular Medicine, 2019, 25, 228-240.	3.5	19
22	2838. Safety and Immunogenicity of a gp120-CD4 Chimeric Subunit Vaccine: A Phase 1a Randomized Controlled Trial. Open Forum Infectious Diseases, 2019, 6, S65-S66.	0.4	0
23	Targeted Bacteria-Specific 18F-Fluoro-Maltohexaose But Not FDG PET Distinguishes Infection From Inflammation. JACC: Cardiovascular Imaging, 2019, 12, 887-889.	2.3	7
24	Production of a chimeric protein and its potential application in sero-diagnosis of Mycoplasma hominis infection. Journal of Microbiological Methods, 2018, 144, 186-191.	0.7	4
25	Identification of Near-Pan-neutralizing Antibodies against HIV-1 by Deconvolution of Plasma Humoral Responses. Cell, 2018, 173, 1783-1795.e14.	13.5	80
26	Merits of FDG PET/CT and Functional Molecular Imaging Over Anatomic Imaging With Echocardiography and CT Angiography for the Diagnosis of Cardiac Device Infections. JACC: Cardiovascular Imaging, 2018, 11, 1679-1691.	2.3	48
27	Diagnostic Value of the Leukocyte Esterase Test for Early Detection of Pleocytosis in Cerebrospinal Fluid of Patients with Suspected Acute Bacterial Meningitis. Infectious Disorders - Drug Targets, 2018, 18, 29-34.	0.4	0
28	Long-term follow-up of elite controllers. Medicine (United States), 2017, 96, e7348.	0.4	10
29	Pathogenesis of Fever. , 2017, , 605-610.e1.		0
30	Urine Vancomycin Level as a Method for Drug Monitoring in Patients With Normal and Decreased Kidney Function. Iranian Journal of Kidney Diseases, 2017, 11, 367-370.	0.1	3
31	Do Biomarkers of Inflammation, Monocyte Activation, and Altered Coagulation Explain Excess Mortality Between HIV Infected and Uninfected People?. Journal of Acquired Immune Deficiency Syndromes (1999), 2016, 72, 206-213.	0.9	95
32	The "100 Days Cough" Was Not Originally Whooping Cough. Open Forum Infectious Diseases, 2016, 3, ofw069.	0.4	0
33	Maintenance of HIV-Specific Memory B-Cell Responses in Elite Controllers Despite Low Viral Burdens. Journal of Infectious Diseases, 2016, 214, 390-398.	1.9	43
34	Light Chain Bias Associated With Enhanced Binding and Function of Anti-HIV Env Glycoprotein Antibodies. Journal of Infectious Diseases, 2016, 213, 156-164.	1.9	18
35	Cocrystal Structures of Antibody N60-i3 and Antibody JR4 in Complex with gp120 Define More Cluster A Epitopes Involved in Effective Antibody-Dependent Effector Function against HIV-1. Journal of Virology, 2015, 89, 8840-8854.	1.5	51
36	Virologic Response Following Combined Ledipasvir and Sofosbuvir Administration in Patients With HCV Genotype 1 and HIV Co-infection. JAMA - Journal of the American Medical Association, 2015, 313, 1232.	3.8	186

#	ARTICLE	IF	CITATIONS
37	Emergence of whooping cough: notes from three early epidemics in Persia. <i>Lancet Infectious Diseases</i> , The, 2015, 15, 1480-1484.	4.6	18
38	Temperature Regulation and the Pathogenesis of Fever. , 2015, , 708-720.e4.		9
39	Epitope target structures of Fc-mediated effector function during HIV-1 acquisition. <i>Current Opinion in HIV and AIDS</i> , 2014, 9, 263-270.	1.5	30
40	Structural Definition of an Antibody-Dependent Cellular Cytotoxicity Response Implicated in Reduced Risk for HIV-1 Infection. <i>Journal of Virology</i> , 2014, 88, 12895-12906.	1.5	108
41	Creegan Congo hemorrhagic fever in Iran. <i>Antiviral Research</i> , 2013, 100, 20-28.	1.9	51
42	Early descriptions of Grisel's syndrome. <i>Child's Nervous System</i> , 2013, 29, 359-360.	0.6	12
43	Elevated hypermutation levels in HIV-1 natural viral suppressors. <i>Virology</i> , 2013, 443, 306-312.	1.1	30
44	Altered T-cell subsets in HIV-1 natural viral suppressors (elite controllers) with hepatitis C infection. <i>Aids</i> , 2013, 27, 1989-1992.	1.0	7
45	Reply to Hartjen et al. <i>Journal of Infectious Diseases</i> , 2013, 208, 184-184.	1.9	0
46	Diverse specificity and effector function among human antibodies to HIV-1 envelope glycoprotein epitopes exposed by CD4 binding. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2013, 110, E69-78.	3.3	138
47	Impact of Persistent HIV Replication on CD4 Negative $\hat{V}132\hat{V}12$ T Cells. <i>Journal of Infectious Diseases</i> , 2012, 205, 1448-1455.	1.9	27
48	Soluble factors from T cells inhibiting X4 strains of HIV are a mixture of $\hat{I}2$ chemokines and RNases. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2012, 109, 5411-5416.	3.3	38
49	Portal Hypertension Secondary to Isolated Liver Tuberculosis. <i>American Journal of Tropical Medicine and Hygiene</i> , 2012, 87, 162-164.	0.6	14
50	Akhawayni and the First Fever Curve. <i>Clinical Infectious Diseases</i> , 2012, 55, 976-980.	2.9	24
51	Signature Biochemical Properties of Broadly Cross-Reactive HIV-1 Neutralizing Antibodies in Human Plasma. <i>Journal of Virology</i> , 2012, 86, 5014-5025.	1.5	12
52	Chronic immune activation and decreased CD4 cell counts associated with hepatitis C infection in HIV-1 natural viral suppressors. <i>Aids</i> , 2012, 26, 1879-1884.	1.0	43
53	Donor Specific Mesenchymal Stem Cells MSCs Transfusion for Desensitization of Resistant Positive Donor Specific Lymphocyte Cross Match and Reduction of Panel Reactive Antibodies PRA. Report of 4 Cases.. <i>Transplantation</i> , 2012, 94, 1062.	0.5	0
54	Donor Specific Mesenchymal Stem Cells MSCs Transfusion for Desensitization of Resistant Positive Donor Specific Lymphocyte Cross Match and Reduction of Panel Reactive Antibodies PRA. Report of 4 Cases.. <i>Transplantation</i> , 2012, 94, 233.	0.5	0

#	ARTICLE	IF	CITATIONS
55	Medical Versus Medical and Surgical Treatment for Brucella Endocarditis. <i>Annals of Thoracic Surgery</i> , 2012, 94, 2141-2146.	0.7	30
56	Correlation Between Circulating HIV-1 RNA and Broad HIV-1 Neutralizing Antibody Activity. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2011, 57, 9-15.	0.9	31
57	IL28B Genotype Does Not Correlate with HIV Control in African Americans. <i>Clinical and Translational Science</i> , 2011, 4, 282-284.	1.5	15
58	The history of facial palsy and spasm. <i>Neurology</i> , 2011, 77, 174-178.	1.5	38
59	Hepatitis C infection in HIV-1 natural viral suppressors. <i>Aids</i> , 2010, 24, 1689-1695.	1.0	32
60	A Young Woman with Diffuse Skin Lesions. <i>Clinical Infectious Diseases</i> , 2010, 51, 195-196.	2.9	0
61	A Young Woman with Diffuse Skin Lesions. <i>Clinical Infectious Diseases</i> , 2010, 51, 248-249.	2.9	0
62	Long-term Nonprogressive Disease Among Individuals With Untreated HIV Infection. <i>JAMA - Journal of the American Medical Association</i> , 2010, 304, 1784.	3.8	2
63	Epidemiologic Characteristics and Natural History of HIV-1 Natural Viral Suppressors. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2009, 50, 403-408.	0.9	62
64	Original Research: Risk Factors for Mortality from Primary Cryptococcosis in Patients with HIV. <i>Postgraduate Medicine</i> , 2009, 121, 107-113.	0.9	6
65	Discordant memory B cell and circulating anti-Env antibody responses in HIV-1 infection. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2009, 106, 3952-3957.	3.3	70
66	Increased expression of suppressor of cytokine signaling-1 (SOCS-1): A mechanism for dysregulated T helper-1 responses in HIV-1 disease. <i>Virology</i> , 2009, 385, 126-133.	1.1	33
67	Natural viral suppressors of HIV-1 have a unique capacity to maintain $\hat{I}^{\hat{I}}$ T cells. <i>Aids</i> , 2009, 23, 1955-1964.	1.0	43
68	Ibn Sina and the Clinical Trial. <i>Annals of Internal Medicine</i> , 2009, 150, 640.	2.0	21
69	Acute Necrotizing Pneumonia in a Previously Healthy Young Adult. <i>Clinical Infectious Diseases</i> , 2008, 46, 266-267.	2.9	2
70	Abdominal Pain and Bacterial Meningitis in a Previously Healthy Young Adult. <i>Clinical Infectious Diseases</i> , 2008, 46, 1479-1480.	2.9	3
71	Tenofovir and Abacavir Combination Therapy: Lessons Learned from an Urban Clinic Population. <i>AIDS Patient Care and STDs</i> , 2007, 21, 240-246.	1.1	7
72	HIV-1 natural viral suppressors: control of viral replication in the absence of therapy. <i>Aids</i> , 2007, 21, 517-519.	1.0	75

#	ARTICLE	IF	CITATIONS
73	A Czech Researcher and Pneumocystis. Clinical Infectious Diseases, 2004, 39, 218-218.	2.9	22